Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.53 |
| ▸ | S100A4 | P26447 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | CASP4 | P49662 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | CASP9 | P55211 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28819780 | 0.84 | TNF (0.53) | PTPRCS100A4ACHEBCHECES1 | |
| SCHEMBL11285711 | 0.83 | CA12 (0.54) | PTPRCS100A4ACHEBCHECES1 | |
| SCHEMBL12284808 | 0.81 | CA12 (0.52) | PTPRCS100A4ACHEBCHECES1 | |
| SCHEMBL516995 | 0.81 | CASP1 (0.63) | PTPRCS100A4ACHEBCHECES1 | |
| SCHEMBL29945629 | 0.81 | CASP1 (0.63) | PTPRCS100A4ACHEBCHECES1 | |
| SCHEMBL28488925 | 0.81 | ALDH1A1 (0.51) | PTPRCS100A4ACHEBCHECES1 | |
| SCHEMBL14648870 | 0.80 | CA12 (0.48) | PTPRCS100A4ACHEBCHECES1 | |
| SCHEMBL12284588 | 0.80 | CA12 (0.48) | PTPRCS100A4ACHEBCHECES1 | |
| SCHEMBL23250129 | 0.80 | CASP3 (0.66) | PTPRCS100A4ACHEBCHECES1 | |
| SCHEMBL29012534 | 0.80 | CA9 (0.57) | PTPRCS100A4ACHEBCHECES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920685-B | Continuous synthesis method of N-alkyl-4-nitrophthalimide | 上海华谊（集团）公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-116903517-A | Preparation method of 4-nitro-N-alkylphthalimide | 广东优巨先进新材料股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-114920685-A | Continuous synthesis method of N-alkyl-4-nitrophthalimide | 上海华谊（集团）公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-2438044-B1 | COMPOUNDS | JAPAN TOBACCO INC (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-8399481-B2 | Compounds | XENTION LTD (GB) | 2013-03-19 | — | — | US | disclosed |
| EP-2438044-A1 | COMPOUNDS | Xention Limited (GB) | 2012-04-11 | — | — | EP | disclosed |
| US-20110136859-A1 | Compounds | XENTION LTD. (GB) | 2011-06-09 | — | — | US | disclosed |
| WO-2010139953-A1 | COMPOUNDS | XENTION LIMITED (GB) | 2010-12-09 | — | — | WO | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| EP-1047672-B1 | PROCESS FOR PREPARING SPARINGLY SOLUBLE AROMATIC AMINES | CIBA SC HOLDING AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| EP-1047672-A1 | PROCESS FOR PREPARING SPARINGLY SOLUBLE AROMATIC AMINES | Ciba SC Holding AG (CH) | 2000-11-02 | — | — | EP | disclosed |
| US-6087480-A | Process for preparing sparingly soluble aromatic amines | CIBA SPECIALTY CHEMCALS CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999036402-A1 | PROCESS FOR PREPARING SPARINGLY SOLUBLE AROMATIC AMINES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1999-07-22 | — | — | WO | disclosed |
| US-4005102-A | METHYLENE CHLORIDE, NITRIC AND SULFURIC ACIDS | GENERAL ELECTRIC COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-3981933-A | SULFURIC ACID, NITRIC ACID, TOLUENE IN METHYLENE CHLORIDE | GENERAL ELECTRIC COMPANY (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | PTPRC 3004/4885S100A4 4607/4885ACHE 3981/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | PTPRC 3004/4885S100A4 4607/4885ACHE 3981/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | PTPRC 3004/4885S100A4 4607/4885ACHE 3981/4885 |
| US-20110136859-A1 | Compounds | CYP2C8, CYP3A7, CYP2A7 | PTPRC 2142/4885S100A4 4591/4885ACHE 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.